IP Library Granted Patent US 7,022,717
Granted Patent B2
US 7,022,717 · App. 10/703,781 · Granted Apr 4, 2006

Chemokine receptor binding heterocyclic compounds

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,022,717
App. No.
10/703,781
Granted
Apr 4, 2006
Kind
B2
Abstract

The present invention is drawn to novel antiviral compounds, pharmaceutical compositions and their use. More specifically this invention is drawn to derivatives of monocyclic polyamines which have activity in standard tests against HIV- or FIV-infected cells as well as other biological activity related to binding of ligands to chemokine receptors that mediate a number of mammalian embryonic developmental processes.

Claims (21)

1. A method to treat atherosclerosis comprises comprising administering to a subject in need of such treatment a compound of the formula

V—CR 2 —Ar 1 —CR 2 NR—(CR 2 ) x —Ar 2

wherein V is a heterocycle of 9–24 members containing 2–4 optionally substituted amine nitrogen atoms spaced from each other by 2 or more optionally substituted carbon atoms, and which heterocycle may optionally comprise a fused aromatic or heteroaromatic ring, and wherein

(a) said heterocycle contains at least one O or S, said O or S spaced from any adjacent heteroatom by at least 2 carbon atoms, and wherein said S is optionally oxidized, or

(b) the heterocycle contains 3 N and at least one carbon atom in said heterocycle is substituted by at least one fluoro substituent, or

(c) both (a) and (b);

and wherein each R is independently H or a straight chain, branched or cyclic alkyl containing 1–6C;

x is 0–4;

Ar 1 is an unsubstituted or substituted aromatic or heteroaromatic moiety; and

Ar 2 is an unsubstituted or substituted aromatic or heterocyclic group; or

the pharmaceutically acceptable salts and protected forms thereof.

2. The method of claim 1 wherein each R is independently H or methyl.

3. The method of claim 1 wherein x is 1.

4. The method of claim 1 wherein Ar 1 is 1,3 or 1,4-phenylene.

5. The method of claim 1 wherein Ar 2 is phenyl or pyridyl.

6. The method of claim 1 wherein V is a 12–16 membered heterocycle.

7. The method of claim 1 wherein V contains O or S as a ring member.

8. The method of claim 1 wherein x is 0–2.

9. The method of claim 1 wherein x is 1–2.

10. The method of claim 7 wherein said S is oxidized.

11. The method of claim 1 wherein at least one carbon in V is substituted by ═O.

Assignments (3)
MERGER AND CHANGE OF NAME Recorded Sep 19, 2014
From: ANORMED INC.; DEMATAL CORP.
To: ANORMED CORPORATION
Reel/Frame 033782/0221 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 15, 2008
From: ANORMED CORPORATION
To: GENZYME CORPORATION
Reel/Frame 020518/0053 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 21, 2005
From: BRIDGER, GARY J.; BOEHRINGER, EVA MARIA; WANG, ZHONGREN; SCHOLS, DOMINIQUE; SKERLJ, RENATO TONY; BOGUCKI, DAVID EARL
To: ANORMED INC.
Reel/Frame 016924/0104 →